Remote Microphone Candidacy Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03897634|
Recruitment Status : Not yet recruiting
First Posted : April 1, 2019
Last Update Posted : June 11, 2019
|First Submitted Date ICMJE||March 20, 2019|
|First Posted Date ICMJE||April 1, 2019|
|Last Update Posted Date||June 11, 2019|
|Estimated Study Start Date ICMJE||July 15, 2019|
|Estimated Primary Completion Date||November 15, 2019 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Change in Abbreviated Profile of Hearing Aid Benefit (APHAB) [ Time Frame: Change from baseline to final appointment will be assessed. Participants will take a baseline at the start of the trial and then complete post-intervention at the end of the 30-day trial. ]
Self assessment, disability based inventory that is used to document outcomes of hearing aid fittings. The APHAB uses a percentile scale (Percent of Problems). This measure has 4 subscales: Ease of communication (EC), Reverberation (RV), Background Noise (BN), and Aversiveness (AV). A lower score indicates a better outcome. We will look at both the global change (defined as EC, RV, and BN scores improving by at least 5 points each) and individual subscales (For EC, RV, or BN a change in 22 points is considered significant and for AV a change of 31 points is needed to be considered significant).
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT03897634 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Change in Speech, Spatial, and Qualities of Hearing (SSQ) [ Time Frame: Change from baseline to final appointment will be assessed. Participants will take a baseline at the start of the trial and then complete post-intervention at the end of the 30-day trial. ]
Questionnaire, clinical patient interview design where participants respond on a scale of 0 to 10, with 10 indicating perfect hearing ability and 0 indicating complete inability.There are 3 subscales calculated by averaged the responses to the questions for each subscale. A change of 2 points is considered a moderate effect with increase in score indicating improvement.
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||Remote Microphone Candidacy Study|
|Official Title ICMJE||Clinical Trial of Roger Adaptive Digital Technology|
Despite improvements in digital hearing aid technology, many hearing aid users continue to report difficulty understanding speech in challenging listening environments. Remote microphones have been shown to provide benefit in the most common of these challenging listening environments: distant speakers, background noise, and reverberation. Despite demonstrated benefit, there is a low rate of remote microphone use among adult hearing aid users. One reason for low uptake may be an uncertainty among hearing healthcare providers and potential users regarding expected clinically relevant benefit. This clinical trial will attempt the following:
2.0 Background / Literature Review / Rationale for the study:
Even when wearing well-fit hearing aids, many individuals with hearing loss continue to report difficulty communicating in background noise is one of the most common complaints of individuals with hearing loss. Directional microphones can improve speech perception in noise, but often fail to provide benefit in cases where the talker is distant from the listener, where there are multiple or moving noise sources, or in reverberation. Digital noise reduction may reduce listening effort and improve listening comfort, but has minimal effect on speech perception.
Placing the microphone in close proximity to the talker reduces the effective distance between speaker and listener, compensating for the effects of background noise and reverberation on the target signal. Use of a remote microphone can significantly improve signal-to-noise ratio (SNR), thereby improving speech perception in noise and at a distance. Recent studies demonstrated that remote-microphone devices that utilize adaptive digital technology (i.e, Roger) provide significantly more benefit for speech understanding in noise than non-adaptive remote microphones. Those advantages are likely related to the adaptive nature of the device, whereby the microphone gain varies according to the level of noise in the environment. In addition, interference is reduced via transmission of short digital bursts (160 μs) across a range of channels (2.4-2.4835 GHz). Further, the ability to utilize the hearing aids' onboard directional microphones in conjunction with a remote microphone gives listeners the benefits of remote microphone use without sacrificing nearfield intelligibility. The Roger system has also been shown to improve cell phone communication amongst cochlear implant patients.
Despite demonstrated advantages, use of remote microphone assistive devices among adults is low. In a recent study of listeners with severe hearing loss—a group which has substantial difficulty communicating in background noise, and is likely to receive significant benefits from remote-microphone devices—less than 10% reported use of a remote microphone. While cost may be a barrier for some users, even when such systems are available for free (as in the Veterans Administration), use is still low. One reason may be uncertainty among both providers and potential users as to expected benefit for a given listener. For example, Lewis et al. failed to demonstrate a clinically-significant benefit of remote microphone use using a work-life outcomes scale in a cohort of mostly nonworking (retired) participants. Wolfe et al. found significant improvements in objective speech recognition on average, but with a wide range of benefit (from 10% to 60% improvement across individual participants). That study also suggested that individual factors may affect remote microphone benefit, in that the magnitude of improved recognition was correlated with the ability to use spatial cues to improve recognition.
All study tasks will take place in the Hearing Aid Lab and/or Northwestern's Center for Audiology, Speech, Language and Learning.
When testing in the Hearing Aid Lab, Frances Searle building room 1-451, we will either use the sound booth or lab space. All hearing related tasks take place in a sound booth which is a sound treated 8'x 8' room within the larger lab space. When taking histories or cognitive measures we will use the office space located within the lab or an additional nearby (i.e. same building) testing room. The additional test room is only used if participant confidentiality can be maintained (i.e. conversation is not audible to those outside the room). When using the Center for Audiology, Speech, Language and Learning all tasks will take place in a sound proof booth, in a clinical Hearing Aid fit room, or the virtual sound environment (ViSoR). ViSoR is a 16' by 14' by 9' space capable of simulating the acoustics and background noise properties of any environment by using an array of speakers.
The trial will use a within-subjects design consisting of baseline assessment (see assessments), hearing aid with Roger connect fitting, a four week trial period of use in the participant's everyday environment(s), and outcome measures.
Participants who qualify for a dome fitting will start their trial the same day as their baseline assessment. Participants who require a custom mold fitting will have earmold impressions taken at their baseline assessment and then be fit with the trial devices after the custom earmold has arrived back in the lab, usually about one week later. During an earmold impression the ear is visually inspected with an otoscope (magnifying scope with light). A cotton block and soft material are placed in the ear. The resulting impression created by the soft material is used to order an earmold for later testing. This is a standard clinical procedure.
A licensed clinical audiologist will perform the assessments, fitting and counseling of hearing aids and Roger system, and conduct the outcome measures. To ensure appropriate fit and use by the participants, there will be a follow-up one week after being fit with the devices. During this appointment participants will be evaluated and their hearing aid logging will be checked for compliance.
Hearing aid/Roger fitting: Trial hearing aids and clinically-appropriate earmolds or domes will be provided by Phonak at no charge to the participants for the duration of the trial. Those aids are expected to be drawn from Phonak's advanced technology level and to provide datalogging via 7 base programs. Aids will be set to NAL-NL2 targets using probe microphone measurements. Directional microphones will be enabled and verified via probe-microphone testing. Roger will be verified via probe-microphone testing, following clinical best practice. Appropriate hearing aid adjustments (as judged by the study audiologist) will be permitted to provide acceptable sound quality and loudness. Final REARs will be recorded. The study audiologist will instruct participants regarding hearing aid and Roger device use. PHAST-R and a Roger competency questionnaire (to be developed with input from Phonak) will be used to document understanding of device function at the fitting and one week follow-up appointments. Participants will then wear the hearing aids and use the Roger system for 1 month in their everyday listening environments. At the completion of the trial, participants will return to the lab for outcome assessments and to provide spontaneous feedback regarding their experiences. Hearing aids and remote microphone will be returned to the study site following completion of the trial.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Not Applicable|
|Study Design ICMJE||Intervention Model: Single Group Assignment
Intervention Model Description:
Within-subject design: Baseline assessments compared to post-trial results.Masking: None (Open Label)
Primary Purpose: Treatment
|Condition ICMJE||Hearing Loss, Sensorineural|
|Intervention ICMJE||Device: Remote Microphone
Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
Other Name: Roger Select
|Study Arms ICMJE||Experimental: Experiences Hearing Aid user
Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
Intervention: Device: Remote Microphone
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Not yet recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||November 15, 2019|
|Estimated Primary Completion Date||November 15, 2019 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years to 85 Years (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||Yes|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT03897634|
|Other Study ID Numbers ICMJE||SP0053453|
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||
|Responsible Party||Pamela Souza, Northwestern University|
|Study Sponsor ICMJE||Northwestern University|
|Collaborators ICMJE||Phonak AG, Switzerland|
|PRS Account||Northwestern University|
|Verification Date||June 2019|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP